TABLE 3.
Factors associated with OS
| All patients | sorafenib | lenvatinib | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | |||||||
| Factor | HR(95% CI) | p‐Value | HR(95% CI) | p‐Value | HR(95% CI) | p‐Value | HR(95% CI) | p‐Value | HR(95% CI) | p‐Value | HR(95% CI) | p‐Value |
| Gender | ||||||||||||
| Female | 1 | 1 | 1 | |||||||||
| Male | 1.25(0.68–2.28) | 0.47 | 1.24(0.6–2.42) | 0.53 | 1.32(0.37–4.74) | 0.67 | ||||||
| Age | ||||||||||||
| 75–79 | 1 | 1 | 1 | |||||||||
| ≥80 | 1.26(0.72–2.2) | 0.43 | 1.22(0.64–2.33) | 0.55 | 1.11(0.38–3.27) | 0.84 | ||||||
| ECOG‐PS | ||||||||||||
| 1/2 | 1 | 1 | 1 | |||||||||
| 0 | 1.2(0.68–2.11) | 0.54 | 0.98(0.49–1.97) | 0.96 | 1.36(0.49–3.78) | 0.56 | ||||||
| Major vascular invasion | ||||||||||||
| VP0/1/2 | 1 | 1 | 1 | |||||||||
| VP3/4 | 1.88(0.83–4.22) | 0.13 | 2.01(0.77–5.28) | 0.16 | 1.81(0.4–8.18) | 0.44 | ||||||
| Extrahepatic spread | ||||||||||||
| Yes | 1 | 1 | 1 | |||||||||
| No | 0.97(0.55–1.71) | 0.9 | 1.03(0.54–1.98) | 0.92 | 1.16(0.33–4.12) | 0.82 | ||||||
| Modified ALBI grade | ||||||||||||
| 2b/3 | 1 | 1 | 1 | 1 | ||||||||
| 1/2a | 0.45(0.26–0.78) | 0.0047 | 0.38(0.21–0.68) | 0.0011 | 0.34(0.17–0.69) | 0.0029 | 0.78(0.25–2.46) | 0.67 | ||||
| mG8 score | ||||||||||||
| ≤10 | 1 | 1 | 1 | |||||||||
| ≥11 | 0.60(0.34–1.05) | 0.07 | 0.85(0.44–1.64) | 0.63 | 0.31(0.11–0.89) | 0.029 | 0.42(0.13–1.38) | 0.15 | ||||
| Intrahepatic tumor volume | ||||||||||||
| <50% | 1 | 1 | 1 | 1 | ||||||||
| ≥50% | 3.31(1.47–7.45) | 0.0038 | 2.80(1.16–6.76) | 0.022 | 2.44(0.94–6.35) | 0.067 | 13.6(2.19–84.3) | 0.0051 | 16.7(1.71–163) | 0.016 | ||
| DCP | ||||||||||||
| <400 mAU/mL | 1 | 1 | 1 | 1 | ||||||||
| ≥400 mAU/mL | 2.23(1.28–3.89) | 0.0047 | 2.08(1.15–3.75) | 0.016 | 1.64(0.87–3.1) | 0.13 | 4.99(1.36–18.3) | 0.015 | 3.92(0.96–16) | 0.057 | ||
| AFP | ||||||||||||
| <400 mAU/mL | 1 | 1 | 1 | 1 | 1 | |||||||
| ≥400 mAU/mL | 1.90(1.02–3.53) | 0.042 | 1.12(0.58–2.19) | 0.73 | 1.21(0.57–2.55) | 0.63 | 4.61(1.37–15.5) | 0.013 | 3.38(0.84–19.7) | 0.031 | ||
| TKI | ||||||||||||
| Sorafenib | 1 | |||||||||||
| Lenvatinib | 0.69(0.38–1.26) | 0.23 | ||||||||||
Abbreviations: ECOG‐PS: the Eastern Cooperative Oncology Group Scale of Performance Status; modified ALBI score: modified albumin–bilirubin score; mG8 score: modified Geriatric 8 score,DCP: des‐gamma‐carboxy prothrombin; AFP: α‐fetoprotein; TKI: tyrosine kinase inhibitor.